Supplementary Material for: Is intravenous and oral Topotecan in Small-Cell Lung Cancer truly equal? A case report

Introduction
Treatment with Topotecan is standard of care therapy for relapsed Small-Cell lung cancer (SCLC). Both oral and intravenous administration of Topotecan have been extensively researched and are found to be equally effective with less adverse events in the oral group.
Case presentation
We report a case of a patient with SCLC, who had previously received oral Topotecan, with radiological stable disease with no changes in tumor or metastasis diameter size after two administrations. Subsequently, this patient received intra-venous Topotecan instead of oral due to supply difficulties. After one administration of intra-venous Topotecan, we saw significant disease regression.
Conclusion
This is to our knowledge the first reported case of better response of intra-venous Topotecan than oral Topotecan. Multiple extrinsic (e.g. food, medication) factors were investigated but could not deliver an explanation.